BELLUS Health Has Sold its Subsidiary Thallion Pharmaceuticals to Taro Pharmaceuticals

In its March 16, 2017 press release, BELLUS Health announced that it had sold its Thallion Pharmaceuticals subsidiary to Taro Parmaceuticals. Included in this sale are all the rights to the drug candidate Shigamab™.

"This transaction supports the further development of ShigamabTM and allows us to focus our efforts on the rest of our pipeline including the recently in-licensed BLU-5937, a drug candidate for chronic cough," said Roberto Bellini, President and Chief Executive Officer of BELLUS Health. "The upfront proceeds from this transaction also meaningfully extend our cash runway to Q4 2018."